Astrazeneca (AZN) Invested Capital (2011 - 2025)

Astrazeneca (AZN) has reported Invested Capital for 18 consecutive years, with $47.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital rose 15.34% year-over-year to $47.3 billion; the TTM figure through Mar 2026 stood at $47.3 billion (up 15.34% YoY), while the FY2025 annual figure was $78.3 billion, up 10.01% from the prior year.
• Invested Capital came in at $47.3 billion for Q1 2026 at Astrazeneca, down from $78.3 billion in the prior quarter.
• The five-year high for Invested Capital was $78.3 billion in Q4 2025, with the low at $35.1 billion in Q3 2022.
• Average Invested Capital over 5 years is $46.9 billion, with a median of $40.7 billion recorded in 2024.
• The largest YoY upside for Invested Capital was 218.74% in 2022 against a maximum downside of 11.6% in 2022.
• Year by year, Invested Capital stood at $66.3 billion in 2022, then advanced by 2.26% to $67.8 billion in 2023, then rose by 4.98% to $71.2 billion in 2024, then advanced by 10.01% to $78.3 billion in 2025, then sank by 39.54% to $47.3 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $47.3 billion, $78.3 billion, and $45.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.